Hibercell, Inc.

Biothera Inc.

Mariana I Nelson

Michael E Danielson

Nandita Bose

Mary A Antonysamy

William J Grossman

Richard M Walsh

Kyle S Michel

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

Methods for identifying beta-glucan binding to immune cells

This disclosure describes, in one aspect, a method for identifying &#x3b2;-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble &#x3b2;-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble &#x3b2;-glucan to bind to the immune cells, and detecting soluble &#x3b2;-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of &#x3b2;-glucan, and co-administering to the subject a soluble &#x3b2;-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

This disclosure describes, in one aspect, a composition that includes a &#x3b2;-glucan component and an antibody component that specifically binds to the &#x3b2;-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to &#x3b2;-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of &#x3b2;-glucan and administering to the subject a composition that comprises a &#x3b2;-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.

Growing community of inventors

Rosemount, MN, United States of America

Mariana I Nelson